Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Sekisui Diagnostics’ OSOM rapid immunochemical fecal occult blood test detects hemoglobin in stool samples as an aid in the early detection of colorectal cancer. The OSOM test provides sample stability: a unique “dry-sample” collection card; value: two patient sample collections on one collection card allow compliance with screening guidelines, using only one test cassette; and a comprehensive physician and patient support Web site.
Working in conjunction with Arotec Diagnostics, The Binding Site offers myeloperoxidase (pANCA) antigen. Antibodies to myeloperoxidase have been observed in systemic vasculitis, glomerulonephritis, rheumatoid arthritis, and inflammatory bowel disease. Elevated plasma levels also have been reported in acute coronary syndromes and with some malignancies.
American Esoteric Laboratories (AEL) has expanded its test offerings for women, with the addition of its Trichomonas amplified probe test, and improved its high-risk HPV testing capabilities.
BioTheranostics’ Prostate Cancer Index is a strong predictor of prostate cancer recurrence and may improve upon the current standard of care for assessing risk of recurrence and metastasis in patients with prostate cancer, according to a study published online in the Proceedings of the National Academy of Sciences (doi:10.1073/pnas.1215870110. Epub March 26, 2013).
BD Diagnostics in April announced an international distributor agreement with Bruker Daltonics to sell and provide frontline technical support for the co-labeled BD Bruker MALDI Biotyper system. The system, combined with automated antimicrobial susceptibility testing on the BD Phoenix microbiology system and BD EpiCenter microbiology data management system, will facilitate a fully integrated, optimized approach for laboratory workflow.
Streck’s CD-Chex CD117 is a flow cytometry control for CD117. The control eliminates the need for laboratories to hold and validate patient samples to use as a control for CD117, saving time and money. CD-Chex CD117 is designed to represent abnormal peripheral blood leukocytes similar to a hematolymphoid neoplastic patient sample. The product has surface CD117 that is detectable with fluorescent monoclonal antibodies by flow cytometry. The CD117 positive abnormal leukocytes are distinguishable from normal leukocytes on the basis of light-scatter properties, a low level of CD45 expression, and heterogeneous CD117 expression.
BioFire Diagnostics has submitted to the FDA its FilmArray blood culture identification (BCID) panel. The panel received the CE Mark earlier this month. The submission comes after completion of clinical trials for the FilmArray BCID panel, which provides automatic results for common infectious causes of sepsis. BioFire anticipates commercial release of the panel this summer, pending FDA clearance.
Randox Toxicology has developed an ELISA that targets UR-144, XLR-11, and additional synthetic cannabinoid compounds, which are commonly found in new “Spice” and “K2” blends. Together with the company’s JWH/AM2201 synthetic cannabinoids ELISA, the UR-144/XLR-11 ELISA provides a comprehensive solution for the rapid detection of more than 55 current synthetic cannabinoids in urine, blood, and oral fluid.
The Center for Phlebotomy Education is holding the Phlebotomy Supervisor’s Boot Camp July 10-12 and Nov. 6-8 in Louisville, Ky. Educators, phlebotomy supervisors, and lab managers who attend will acquire new skills and strategies for staff development, technical instruction, mentoring, and coaching professionalism. The presenters are Catherine Ernst, RN, PBT(ASCP), Lisa Steinam, PBT(ASCP), and Dennis Ernst, MT(ASCP).
With a recent software upgrade (V2.5/2.3.0.0) and new adapter for its Clinitek Status Connect urine chemistry system, Siemens Healthcare Diagnostics now offers hospitals and clinicians seamless wireless connectivity and improved bar-coding capabilities for point-of-care urinalysis testing. These enhancements enable greater flexibility, risk management, and speed.
